With the advent of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in melanoma physicians are no longer using BRAF inhibitors alone, but rather in combination with MEK inhibitors due to the improved efficacy.
Original Article: Updates in Targeted Combination Therapies for Melanoma
NEXT ARTICLE